We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study.
- Authors
Kobelt, G; Jönsson, L; Young, A; Eberhardt, K
- Abstract
The cost per quality-adjusted life-year (QALY) of infliximab (Remicade) treatment in rheumatoid arthritis (RA) was estimated on the basis of a clinical trial comparing infliximab plus methotrexate with methotrexate alone in 428 patients with advanced disease [Anti-Tumour Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy (ATTRACT)].
- Publication
Rheumatology (Oxford, England), 2003, Vol 42, Issue 2, p326
- ISSN
1462-0324
- Publication type
Journal Article
- DOI
10.1093/rheumatology/keg107